California SB1224: The California Emerging Therapies Research Partnership Act.

What the bill says

An act to add Division 10.3 (commencing with Section 11730) to the Health and Safety Code, relating to controlled substances, and making an appropriation therefor. controlled substances, and making an appropriation therefor The California Emerging Therapies Research Partnership Act. Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 schedules and places the greatest restrictions and penalties on the use of substances placed in Schedule I…

From the committee substitute text, June 11, 2026:

An act to add Division 10.3 (commencing with Section 11730) to the Health and Safety Code, relating to controlled substances, and making an appropriation therefor. controlled substances, and making an appropriation therefor The California Emerging Therapies Research Partnership Act. Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 schedules and places the greatest restrictions and penalties on the use of substances placed in Schedule I. Existing law classifies, among others, psilocybin, ibogaine, and dimethyltryptamine as Schedule I substances, classifies ketamine as a Schedule III substance, and prohibits various actions related to those substances, including their sale, possession, transportation, manufacture, or cultivation. Existing law authorizes a person who is lawfully entitled to use specified controlled substances under applicable federal laws or regulations to obtain and use those substances for approved purposes in bona fide research, instruction, or analysis. This bill, the California Emerging Therapies Research Partnership Act, would establish the California Emerging Therapies Research Partnership Fund, a continuously appropriated fund, within the State Treasury, to be administered by the State Department of Health Care Services (department) and the Department of Veterans Affairs, to, among other things, issue grants to a University of California campus to serve as an anchor institution for a federally registered emerging therapies clinical trial. The bill would define “emerging therapies” for these purposes …

Read the full official text

Sponsors

• Brian Jones (R, SD40) · primary sponsor
• Josh Becker (D, SD13)
• Scott Wiener (D, SD11)
• Josh Lowenthal (D, AD69)
• Laurie Davies (R, AD74)
• Jeff Gonzalez (R, AD36)

Latest actions

1. August 13, 2026: August 13 hearing: Held in committee and under submission.
2. August 5, 2026: August 5 set for first hearing. Placed on suspense file.
3. July 1, 2026: From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 30). Re-referred to Com. on APPR.
4. July 1, 2026: Coauthors revised.
5. June 24, 2026: From committee: Do pass and re-refer to Com. on M. & V.A. (Ayes 14. Noes 0.) (June 23). Re-referred to Com. on M. & V.A.
6. June 15, 2026: Re-referred to Coms. on HEALTH and M. & V.A. pursuant to Assembly Rule 96.
7. June 11, 2026: From committee with author's amendments. Read second time and amended. Re-referred to Com. on INS.
8. June 4, 2026: Referred to Com. on INS.
9. May 28, 2026: In Assembly. Read first time. Held at Desk.
10. May 28, 2026: Read third time. Passed. (Ayes 39. Noes 0. Page 4526.) Ordered to the Assembly.

Votes

• Do pass and be re-referred to the Committee on [Appropriations] (June 30, 2026): 8 yea, 0 nay, passed
• Do pass and be re-referred to the Committee on [Military and Veterans Affairs] (June 23, 2026): 14 yea, 0 nay, passed
• Special Consent SB1224 Jones (May 28, 2026): 39 yea, 0 nay, passed
• Do pass as amended (May 14, 2026): 7 yea, 0 nay, passed
• Placed on suspense file (May 4, 2026): 7 yea, 0 nay, passed
• Do pass, but first be re-referred to the Committee on [Appropriations] (April 22, 2026): 7 yea, 0 nay, passed

Common questions

What is SB1224?

SB1224 is a bill in the California Legislature (2025-2026 Regular Session): The California Emerging Therapies Research Partnership Act.

What does SB1224 do?

In its own words: An act to add Division 10.3 (commencing with Section 11730) to the Health and Safety Code, relating to controlled substances, and making an appropriation therefor. controlled substances, and making an appropriation therefor The California Emerging Therapies Research Partnership Act. Existing law, the California Uniform Controlled Substances Act, classifies controlled substances into 5 schedules and places the greatest restrictions and penalties on the use of substances placed in Schedule I…

What is the status of SB1224?

In committee as of August 13, 2026. Latest action: August 13 hearing: Held in committee and under submission. (August 13, 2026).

Who sponsored SB1224?

Brian Jones (R, SD40), with 5 co-sponsors.

Where is the official record for SB1224?

On the California Legislature website: https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202520260SB1224